{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:09:32Z","timestamp":1782860972662,"version":"3.54.5"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.jsat.2016.08.002","type":"journal-article","created":{"date-parts":[[2016,8,13]],"date-time":"2016-08-13T03:32:07Z","timestamp":1471059127000},"page":"81-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["Non-Prescribed Buprenorphine in New York City: Motivations for Use, Practices of Diversion, and Experiences of Stigma"],"prefix":"10.1016","volume":"70","author":[{"given":"Bennett","family":"Allen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Harocopos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2016.08.002_bb0005","series-title":"Advancing access to addiction medications: implications for opioid addiction treatment","author":"American Society of Addiction Medicine","year":"2013"},{"key":"10.1016\/j.jsat.2016.08.002_bb0010","series-title":"The standards of care for the addiction specialist physician","author":"American Society of Addiction Medicine","year":"2014"},{"key":"10.1016\/j.jsat.2016.08.002_bb0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jama.285.1.39","article-title":"Deaths attributable to methadone vs. buprenorphine in France","volume":"285","author":"Auriacombe","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jsat.2016.08.002_bb0020","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.drugalcdep.2014.12.002","article-title":"Illicit use of opioid substitution drugs: Prevalence, user characteristics, and the association with non-fatal overdoses","volume":"147","author":"Bretteville-Jensen","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2016.08.002_bb0025","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1086\/508184","article-title":"Buprenorphine use: The international experience","volume":"43","author":"Carrieri","year":"2006","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.jsat.2016.08.002_bb0030","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.drugalcdep.2011.09.029","article-title":"Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids","volume":"122","author":"Daniulaityte","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2016.08.002_bb0035","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0376-8716(98)00028-3","article-title":"Self-report among injecting drug users: A review","volume":"51","author":"Darke","year":"1998","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2016.08.002_bb0040","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jsat.2014.07.015","article-title":"Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants","volume":"48","author":"Fox","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2016.08.002_bb0045","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/08897077.2013.804484","article-title":"I heard about it from a friend: Assessing interest in buprenorphine treatment","volume":"35","author":"Fox","year":"2014","journal-title":"Substance Abuse"},{"key":"10.1016\/j.jsat.2016.08.002_bb0050","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1016\/j.addbeh.2013.08.008","article-title":"Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, Maryland","volume":"38","author":"Genberg","year":"2013","journal-title":"Addictive Behaviors"},{"key":"10.1016\/j.jsat.2016.08.002_bb0055","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF02766777","article-title":"Criteria for assessing the trustworthiness of naturalistic inquiries","volume":"29","author":"Guba","year":"1981","journal-title":"Educational Communication and Technology"},{"key":"10.1016\/j.jsat.2016.08.002_bb0060","series-title":"Applied thematic analysis","author":"Guest","year":"2011"},{"key":"10.1016\/j.jsat.2016.08.002_bb0065","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.drugpo.2015.12.021","article-title":"Circumstances and contexts of heroin initiation following non-medical opioid analgesic use in New York City","volume":"28","author":"Harocopos","year":"2016","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.jsat.2016.08.002_bb0070","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1477-7517-10-24","article-title":"\u2018Diversion\u2019 of methadone or buprenorphine: \u2018Harm\u2019 versus \u2018helping\u2019","volume":"10","author":"Havnes","year":"2013","journal-title":"Harm Reduction Journal"},{"key":"10.1016\/j.jsat.2016.08.002_bb0075","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.drugalcdep.2011.07.019","article-title":"Diversion and abuse of buprenorphine: Findings from national surveys of treatment patients and physicians","volume":"120","author":"Johanson","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2016.08.002_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10550887.2014.975617","article-title":"Diversion of methadone and buprenorphine from opioid substitution treatment: Patients who regularly sell or share their medication","volume":"31","author":"Johnson","year":"2015","journal-title":"Journal of Addictive Diseases"},{"key":"10.1016\/j.jsat.2016.08.002_bb0085","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drugpo.2014.10.003","article-title":"Diversion of methadone and buprenorphine by patients in opioid substitution treatment in Sweden: Prevalence estimates and risk factors","volume":"26","author":"Johnson","year":"2015","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.jsat.2016.08.002_bb0090","first-page":"e41","article-title":"Trends in prescriptions for oxycodone and other commonly used opioids in the United States, 2000-2010","volume":"6","author":"Kenan","year":"2012","journal-title":"Open Medicine"},{"key":"10.1016\/j.jsat.2016.08.002_bb0095","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.drugalcdep.2013.12.005","article-title":"The diversion and injection of a buprenorphine-naloxone soluble film formulation","volume":"136","author":"Larance","year":"2014","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2016.08.002_bb0100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jsat.2014.02.003","article-title":"Abuse and diversion of buprenorphine sublingual tablets and film","volume":"47","author":"Lavonas","year":"2014","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2016.08.002_bb0105","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.drugalcdep.2012.05.025","article-title":"Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine","volume":"126","author":"Lofwall","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2016.08.002_bb0110","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jsat.2011.04.008","article-title":"Efficacy of continuing medical education to reduce the risk of buprenorphine diversion","volume":"41","author":"Lofwall","year":"2011","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2016.08.002_bb0115","doi-asserted-by":"crossref","first-page":"401","DOI":"10.36076\/ppj.2010\/13\/401","article-title":"Therapeutic use, abuse, and nonmedical use of opioids: A ten-year perspective","volume":"13","author":"Manchikanti","year":"2010","journal-title":"Pain Physician"},{"key":"10.1016\/j.jsat.2016.08.002_bb0120","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jsat.2014.07.002","article-title":"Injection and sexual HIV\/HCV risk behaviors associated with nonmedical use of prescription opioids among young adults in New York City","volume":"48","author":"Mateu-Gelabert","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2016.08.002_bb0125","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jsat.2015.04.010","article-title":"Prior experience with non-prescribed buprenorphine: Role in treatment entry and retention","volume":"57","author":"Monico","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2016.08.002_bb0130","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/10550880903014767","article-title":"Diversion of buprenorphine\/naloxone coformulated tablets in a region with high prescribing prevalence","volume":"28","author":"Monte","year":"2009","journal-title":"Journal of Addictive Diseases"},{"key":"10.1016\/j.jsat.2016.08.002_bb0135","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/dar.12079","article-title":"Regaining control: the patient experience of supervised compared with unsupervised consumption in opiate substitution treatment","volume":"33","author":"Notley","year":"2014","journal-title":"Drug and Alcohol Review"},{"key":"10.1016\/j.jsat.2016.08.002_bb0140","series-title":"Unintentional drug poisoning (overdose) deaths involving opioids in New York City, 2000\u20132013. New York City Department of Health and Mental Hygiene Epi data brief, 50","author":"Paone","year":"2014"},{"key":"10.1016\/j.jsat.2016.08.002_bb0145","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.drugalcdep.2015.08.007","article-title":"Buprenorphine infrequently found in fatal overdose in New York City","volume":"155","author":"Paone","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2016.08.002_bb0150","series-title":"Qualitative research and evaluation methods","author":"Patton","year":"2001"},{"key":"10.1016\/j.jsat.2016.08.002_bb0155","first-page":"1487","article-title":"Vital signs: Overdoses of prescription opioid pain relievers\u2014United States, 1999-2008","volume":"60","author":"Paulozzi","year":"2011","journal-title":"Centers for Disease Control and Prevention Mortality and Morbidity Weekly Report"},{"key":"10.1016\/j.jsat.2016.08.002_bb0160","unstructured":"Recovery Enhancement for Addiction Treatment Act of 2014, S. 2645, 113th Cong. (2013-2014)"},{"key":"10.1016\/j.jsat.2016.08.002_bb0165","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7517-10-27","article-title":"Illicit use of methadone and buprenorphine among adolescents and young adults in Sweden","volume":"10","author":"Richert","year":"2013","journal-title":"Harm Reduction Journal"},{"key":"10.1016\/j.jsat.2016.08.002_bb0170","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3109\/10826084.2012.680172","article-title":"Messages about methadone and buprenorphine in reality television: A content analysis of Celebrity Rehab with Dr. Drew","volume":"47","author":"Roose","year":"2012","journal-title":"Substance Use and Misuse"},{"key":"10.1016\/j.jsat.2016.08.002_bb0175","first-page":"32","article-title":"Buprenorphine treatment for narcotic addiction: Not without risks","volume":"12","author":"Sansone","year":"2015","journal-title":"Innovations in Clinical Neuroscience"},{"key":"10.1016\/j.jsat.2016.08.002_bb0180","article-title":"Non-prescribed use of opioid substitution medication: Patterns and trends in sub-populations of opioid users","author":"Schulte","year":"2015","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.jsat.2016.08.002_bb0185","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jsat.2010.03.014","article-title":"Self-treatment: Illicit buprenorphine use by opioid-dependent treatment seekers","volume":"39","author":"Schuman-Olivier","year":"2010","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2016.08.002_bb0190","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1080\/10550490802268835","article-title":"Attitudes toward buprenorphine and methadone among opioid-dependent individuals","volume":"17","author":"Schwartz","year":"2008","journal-title":"American Journal on Addictions"},{"key":"10.1016\/j.jsat.2016.08.002_bb0195","doi-asserted-by":"crossref","first-page":"407","DOI":"10.5055\/jom.2013.0183","article-title":"Awareness of, experience with, and attitudes toward buprenorphine among opioid users visiting a New York City syringe exchange program","volume":"9","author":"Shah","year":"2013","journal-title":"Journal of Opioid Management"},{"key":"10.1016\/j.jsat.2016.08.002_bb0200","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jsat.2014.07.010","article-title":"Supply of buprenorphine waivered physicians: The influence of state policies","volume":"48","author":"Stein","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2016.08.002_bb0205","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/14659891.2010.526480","article-title":"Comparing methadone and Suboxone in applied treatment settings: The experiences of maintenance patients in Lanarkshire","volume":"16","author":"Tanner","year":"2011","journal-title":"Journal of Substance Use"},{"key":"10.1016\/j.jsat.2016.08.002_bb0210","series-title":"Paper presented at the Association for Medical Education and Research in substance abuse 39th annual National Conference, Washington, DC","article-title":"Longitudinal patterns of buprenorphine-naloxone prescription-filling among New York City residents, 2011\u20132013","author":"Tuazon","year":"2015"},{"key":"10.1016\/j.jsat.2016.08.002_bb0215","series-title":"Opioid overdose: preventing and reducing opioid overdose mortality","author":"United Nations Office on Drugs and Crime & World Health Organization","year":"2013"},{"key":"10.1016\/j.jsat.2016.08.002_bb0220","series-title":"SAMHSA evaluation of the impact of the DATA waiver program: summary report","author":"Westat, & Avisa Group","year":"2006"},{"key":"10.1016\/j.jsat.2016.08.002_bb0225","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/10550880903028841","article-title":"What is diversion of buprenorphine and how common is it?","volume":"28","author":"Winstock","year":"2009","journal-title":"Journal of Addictive Diseases"},{"key":"10.1016\/j.jsat.2016.08.002_bb0230","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/10550887.2011.642757","article-title":"The emerging buprenorphine epidemic in the United States","volume":"31","author":"Wish","year":"2012","journal-title":"Journal of Addictive Diseases"},{"key":"10.1016\/j.jsat.2016.08.002_bb0235","series-title":"Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence","author":"World Health Organization","year":"2009"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074054721630006X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074054721630006X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:45:13Z","timestamp":1760039113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S074054721630006X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":47,"alternative-id":["S074054721630006X"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2016.08.002","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-Prescribed Buprenorphine in New York City: Motivations for Use, Practices of Diversion, and Experiences of Stigma","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2016.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}